The most debated possible biomarkers involve HER2-receptor status, polymorphisms in genes, such as BRCA1/2, TP53 and PTEN [47,48,49], the level of plasma-VEGF-A and, recently, hypertension. The gene discussed is VEGFA; the disease is hypertensive disorder.